Our Solutions   Peg L Aspatero Injection

Peg L Aspatero Injection

Peg L Aspatero Injection

*To be consumed as directed by physician.

Therapies:

Anti Neoplastics

Composition:

PEG L - Asparaginase 3750 IU/5 ml

About Peg L Aspatero Injection

Peg L Aspatero 3750 IU Injection contains Asparaginase 3750 IU, an antineoplastic (anticancer) enzyme used in the treatment of Acute Lymphoblastic Leukemia (ALL) as part of combination chemotherapy. It works by breaking down asparagine, an amino acid that leukemia cells require for growth and survival. Since leukemia cells cannot produce sufficient asparagine on their own, depletion of this nutrient inhibits cancer cell growth and promotes their destruction while enhancing the effectiveness of chemotherapy. Peg L Aspatero should be administered only under the supervision of an experienced oncology specialist.

Peg L Aspatero Injection

*To be consumed as directed by physician.


Usage Instructions

  • Peg L Aspatero 3750 IU Injection should only be administered by a qualified healthcare professional.
  • The dose, route of administration, and treatment schedule are determined by your oncologist based on your body size, treatment protocol, and response to therapy.
  • Regular monitoring of blood counts, blood glucose, liver function, kidney function, and treatment response is recommended throughout therapy.
  • Do not miss scheduled treatment sessions or discontinue treatment unless instructed by your doctor.
  • Adequate hydration is recommended during treatment.

    • Benefits and Use

  • Peg L Aspatero 3750 IU Injection is indicated for the treatment of Acute Lymphoblastic Leukemia (ALL) as part of combination chemotherapy.
  • It works by depriving leukemia cells of asparagine, an essential amino acid required for their survival, thereby slowing cancer cell growth and promoting cell death.
  • When used according to established chemotherapy protocols, it improves treatment effectiveness, supports disease control, and contributes to better clinical outcomes in patients.

    • Safety Information

  • Pregnancy:
  • Peg L Aspatero should not be used during pregnancy unless the potential benefits outweigh the risks. Effective contraception should be used by both men and women during treatment and for the period recommended by your doctor after therapy.
  • Breastfeeding:
  • Breastfeeding is not recommended during treatment unless specifically advised by your physician.
  • Alcohol:
  • Consult your doctor before consuming alcohol while receiving this medicine.
  • Kidney Disorders:
  • Use with caution in patients with severe kidney disease; dose adjustment and monitoring may be required.
  • Liver Disorders:
  • Liver function should be monitored regularly during treatment, especially in patients with existing liver disease.
  • Blood Sugar:
  • Peg L Aspatero may increase blood glucose levels. Patients, particularly those with diabetes, should monitor blood sugar regularly.
  • Infection Risk:
  • This medicine may reduce the body's ability to fight infections. Seek immediate medical attention if you develop fever, sore throat, persistent cough, or other signs of infection.
  • Driving:
  • Avoid driving or operating machinery if you experience dizziness, fatigue, or other symptoms that affect alertness.
  • Inform your doctor immediately if you develop severe allergic reactions, rash, swelling, difficulty breathing, persistent vomiting, unusual bleeding, or severe abdominal pain.

    • Ingredients

    PEG L - Asparaginase 3750 IU/5 ml

    How to Use

  • Peg L Aspatero 3750 IU Injection is administered by a healthcare professional as an intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection, depending on the prescribed treatment protocol.
  • Do not self-administer.
  • Drink plenty of fluids during treatment and follow your doctor's instructions regarding blood tests and follow-up appointments.

    • Storage Information

  • Store below 30°C in the original packaging, protected from light and moisture.
  • Do not freeze.